Bayer Aktiengesellschaft (BAYRY)
| Market Cap | 29.04B |
| Revenue (ttm) | 50.95B |
| Net Income (ttm) | -3.15B |
| Shares Out | 3.93B |
| EPS (ttm) | -3.20 |
| PE Ratio | n/a |
| Forward PE | 1.37 |
| Dividend | $0.03 (0.40%) |
| Ex-Dividend Date | Apr 29, 2024 |
| Volume | 1,409,081 |
| Open | 7.43 |
| Previous Close | 7.27 |
| Day's Range | 7.34 - 7.48 |
| 52-Week Range | 6.96 - 16.46 |
| Beta | 0.97 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 27, 2024 |
About BAYRY
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter med... [Read more]
News
Bayer CEO wins first AGM shareholder vote
Bayer CEO Bill Anderson on Friday won a vote of confidence at his first annual general meeting (AGM) at the helm of the embattled healthcare and agriculture group, defying a challenge from one German ...
Bayer investor Deka takes a stand against CEO in annual vote
Bayer shareholder Deka Investment said on Friday it would not join other large investors in supporting the healthcare and agriculture group's management at its annual general meeting.
Bayer Introduces Iberogast™ in the U.S., Bringing Proven Plant-Based Relief to the Millions Who Experience Gut Health Issues
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Introduces Iberogast™ in the U.S., Bringing Proven Plant-Based Relief to the Millions Who Experience Gut Health Issues.
Bayer confirms outlook despite slow businesses in agriculture, consumer health
Bayer on Monday confirmed its full-year guidance for earnings and cash flow despite slow business at its crop science and consumer health divisions.
Bayer's patent for blood thinner Xarelto invalid, UK court rules
Bayer's patent covering its best-selling blood thinner Xarelto is invalid, London's High Court ruled on Friday in a blow to the German drugmaker.
Bayer and Google Cloud to accelerate development of AI-powered healthcare applications for radiologists
LAS VEGAS--(BUSINESS WIRE)--Bayer and Google Cloud today announced a collaboration on the development of artificial intelligence (AI) solutions to support radiologists and ultimately better serve pati...
Bayer's Consumer Health Division Announces Changes to North America Leadership Team
WHIPPANY, N.J.--(BUSINESS WIRE)--Today, Bayer announced Samantha Avivi as the new Chief Marketing Officer (CMO) for its Consumer Health division in North America. She will report directly to Dave Toma...
Google partners with Bayer on new AI product for radiologists
Google Cloud and Bayer are building a new AI-powered platform to help radiologists work more efficiently.
Judge slashes Bayer $1.56 billion Roundup verdict to $611 million
A Missouri judge slashed a $1.56 billion verdict against Bayer to $611 million for three people who claimed its Roundup weed killer caused their cancer, by reducing punitive damages. Bayer said on Fri...
Federman & Sherwood Investigates Bayer Heritage Federal Credit Union for Data Breach
OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Bayer Heritage Federal Credit Union for Data Breach.
Bayer Appoints Sue Ann Pentecost as Vice President, Head of U.S. Pharmaceutical Communications
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced Sue Ann Pentecost as the new Vice President, Head of Pharmaceuticals Communications in the United States. She will report directly to Beth Roden,...
Bayer says 2024 sales of prostate cancer drug above $1 bln
Bayer on Thursday predicted at least $1 billion in 2024 sales for prostate cancer drug Nubeqa, which is playing a bigger role for the drugmaker's growth prospects after the failure of a promising anti...
Bayer and Thermo Fisher Scientific Collaborate to Increase Patient Access to Precision Cancer Medicines
BERLIN & CARLSBAD, Calif.--(BUSINESS WIRE)--Bayer AG and Thermo Fisher Scientific Inc. today announced a collaboration to develop next-generation sequencing (NGS)-based companion diagnostic assays (CD...
Bayer Pharmaceuticals streamlines Leadership Team for next phase of growth
BERLIN--(BUSINESS WIRE)--Bayer's Pharmaceutical Division is set to embark on its next phase of growth, reshaping its executive Leadership Team to become more mission-centric and value focused. The com...
Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines
BERLIN & CARLSBAD, Calif.--(BUSINESS WIRE)--Bayer AG and Thermo Fisher Scientific Inc. today announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. The...
Positive topline results from Phase III long-term study OASIS 3 support submissions for marketing authorization for Bayer's elinzanetant
BERLIN--(BUSINESS WIRE)--Bayer today announced positive topline results of the Phase III study OASIS 3 evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus ...
Bayer to seek approval for menopausal relief drug after third trial win
Bayer said on Tuesday that it would request regulatory approval for its menopause drug after the daily pill was shown to ease hot flashes in a third late-stage trial, providing some relief for its pha...
Bayer CEO: Roundup is 'safe,' and litigation is driving prices up
Life sciences company Bayer (BAYRY, BAYN.DE) isn't breaking itself up right now.
Bayer and Aignostics to collaborate on next generation precision oncology
Not intended for UK Media Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development, further strengthening Bayer's precisio...
Bayer CEO on turnaround strategy: We've taken out multiple levels of hierarchy
Bayer CEO Bill Anderson joins 'Squawk on the Street' to discuss why the company hasn't broken up parts of the business, why the current strategy is the best way to go, and more.
Major Bayer shareholder Harris backs CEO's focus on internal restructuring
Top three Bayer shareholder Harris Associates on Thursday came out in strong support of the drugmaker's strategy to suspend work on a separation of the diversified group and to focus on improving the ...
Bayer share price is in a freefall: is it safe to buy the dip?
Bayer (ETR: BAYN) share price has been in a strong freefall and it sits at its lowest level in almost 20 years. The stock crashed to a low of €25.57 on Thursday, making it the worst-performing company...
Bayer Wins Third Consecutive Trial Victory
WHIPPANY, N.J.--(BUSINESS WIRE)--Today Bayer won its third consecutive trial victory when a jury reached a defense verdict in its most recent trial – the Kline Roundup™ product liability trial – befor...
Bayer purchases heart drug for up to $310 mln
Bayer said on Monday it acquired the exclusive marketing rights for Europe for a new drug that is under regulatory review to treat a rare, potentially fatal heart disease for up to $310 million upfron...
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe
BridgeBio Pharma has granted German drugmaker Bayer an exclusive license to commercialize its heart disease drug in Europe, the companies said on Monday.